What the researchers examined
The review focuses on patients with cancer receiving or having received neurotoxic anticancer treatment. The researchers examined links between their blood concentration of 25-hydroxyvitamin D, the chosen marker of vitamin D status, and the occurrence or severity of chemotherapy-related peripheral neuropathy.
The protocol had been registered in PROSPERO before the review was conducted. The literature search covered three databases through June 23, 2026. Fourteen publications contributed data, but each pooled quantitative analysis was based on only two studies. The supplied abstract specifies neither the total number of patients nor the follow-up durations.
A signal that depends on the statistical model
For severe neuropathy, pooling the adjusted estimates yields an odds ratio of 1.81 with a common-effect model, and a 95% confidence interval of 1.32 to 2.49. With a random-effects model, which accounts for differences between studies, the estimate rises to 2.94, but the interval widens considerably, from 0.63 to 13.73. It then includes no association.
For any neuropathy, regardless of severity, the association remains present in both models, but heterogeneity remains substantial. These odds ratios cannot be used to calculate how many additional patients would be affected without knowing the absolute risks in the groups being compared.
Why this does not prove that a supplement helps
Most of the data had a high or very high risk of bias. The authors therefore describe their findings as exploratory, useful for generating a hypothesis rather than confirming it. The signal appeared to be present particularly when vitamin D was measured before treatment or at the start of follow-up, without establishing a causal link.
The crucial distinction is between blood status and an intervention: observing more neuropathy in patients with low vitamin D does not demonstrate that raising their levels would prevent it. The abstract provides no evidence that supplementation is effective and offers no basis for deriving a dose.
Limitations to keep in mind
Analysis based solely on the supplied PubMed abstract, without consulting the full text. Each pooled analysis relies on two studies, with substantial heterogeneity and predominantly high or very high risks of bias. Total sample sizes, follow-up durations, funding and conflicts of interest could not be verified.
What we can take away
This review supports a hypothesis to test, not a prevention strategy: low vitamin D status could accompany an increased risk of chemotherapy-related neuropathy, with no demonstrated benefit from supplements.
Sources and provenance
- Vitamin D status and chemotherapy-induced peripheral neuropathy in patients with cancer: a systematic review with exploratory quantitative synthesis.
Source date: 2026-11-07.
Journal Article, Systematic Review, Review · Résumé PubMed uniquement, texte intégral non consulté


